EICHORCondition: Painful Lumbosacral Radiculopathy · Sponsor: Vertex Pharmaceuticals Incorporated
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Hope Research Institute | Phoenix, Arizona, United States | — |
| Arizona Research Center | Phoenix, Arizona, United States | — |
| Trovare Clinical Research | Bakersfield, California, United States | — |
| Velocity Clinical Research - Banning | Banning, California, United States | — |
| Velocity Clinical Research - San Diego | La Mesa, California, United States | — |
| Probe Clinical Research | Riverside, California, United States | — |
| Pain Management and Injury Relief | Thousand Oaks, California, United States | — |
| Visionary Investigators Network | Aventura, Florida, United States | — |
| Nature Coast Clinical Research - Crystal River | Crystal River, Florida, United States | — |
| JY Research Institute | Cutler Bay, Florida, United States | — |
| Fleming Island Center for Clinical Research | Fleming Island, Florida, United States | — |
| Convenient Medical Research | Hialeah, Florida, United States | — |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06176196